P
PregLem
Biotech & Life Sciences · Geneva, Switzerland · Founded 2006
Swiss-based specialty biopharmaceutical company dedicated to the development and commercialization of innovative drugs for women’s reproductive medicine MoreLess
Preglem is a healthcare company specializing in the development of innovative treatments for uterine fibroids and endometriosis, two prevalent benign gynecological conditions affecting women of reproductive age. These conditions often lead to significant physical morbidity and impaired quality of life, making effective treatment crucial. Preglem operates in the reproductive medicine market, focusing on pioneering first-in-class medical treatments that change the rules of treatment and drug performance. The company serves healthcare providers and patients, offering advanced therapeutic solutions that aim to preserve the integrity of womanhood. Preglem's business model involves research and development, followed by commercialization of their treatments through exclusive licensing agreements, such as their partnership with Myovant Sciences to commercialize Relugolix Combination Tablet in specific territories outside the U.S. Revenue is generated through the sale of these specialized treatments and licensing agreements. Keywords: uterine fibroids, endometriosis, reproductive medicine, innovative treatments, women's health, gynecological conditions, drug development, licensing agreements, healthcare providers, quality of life.
Company overview
PregLem company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2006
- Headquarters
- Geneva, Switzerland
- Employees
- 104
- Open positions
- None listed
- Dealroom signal
- 65.0
Valuation & funding
PregLem funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Oct 2010 | $461M | $461M | Gedeon Richter | — |
| SERIES BOther financing | Dec 2007 | $33M | $132M | Sofinnova Partners · MVM Life Science Partners · NeoMed · Sofinnova Investments | — |
| SERIES AOther financing | Jun 2007 | $29M | $117M | NeoMed · Sofinnova Partners · MVM Life Science Partners | — |
Financials
Revenue and workforce over time
Available revenue and workforce history. Fields without reported data are omitted.
| Year | Revenue | Growth | Employees |
|---|---|---|---|
| 2026 | $4.9M | 0% | 104 |
| 2025 | $4.9M | 0% | 141 |
| 2024 | $4.9M | 0% | 141 |
| 2023 | $4.9M | 0% | 141 |
| 2022 | $4.9M | 0% | 141 |
| 2021 | $4.9M | 0% | 156 |
| 2020 | $4.9M | — | 163 |
Growth signals
PregLem website traffic
Latest recorded traffic for PregLem is 160 monthly website visits, up 6.7% over the last three months. PregLem's team declined 26.2% over the past year.
Comparisons
PregLem compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
PregLem's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where PregLem has talent and traffic
team presence
In the news
Latest news about PregLem
Recent press, funding announcements, and product moves mentioning PregLem — open to read from the original sources.
Market sentiment
What the market is saying about PregLem
An AI-synthesized read of the highest-engagement posts about PregLem on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See PregLem’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.